Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Prospective Real-world Study of Zanubrutinib Combined With Rituximab (ZR) in the First-line Treatment for Patients With Marginal Zone Lymphoma (MZL)

NCT07233720 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07233720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07233720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Prospective Real-world Study of Zanubrutinib Combined With Rituximab (ZR) in the First-line Treatment for Patients With Marginal Zone Lymphoma (MZL)
Lead sponsor
Henan Cancer Hospital
Phase
Observational
Overall status
Recruiting
Start date
November 18, 2025
Completion date
June 30, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma